Heartflow, Inc. is a software and artificial intelligence company that provides a non-invasive solution for diagnosing and managing coronary artery disease. The company’s Heartflow Platform leverages AI and computational fluid dynamics to create personalized 3D models of a patient’s heart from a single coronary computed tomography angiography scan. This technology delivers insights on blood flow, stenosis, plaque volume, and plaque composition to support risk stratification and treatment planning. The platform includes the Heartflow RoadMap Analysis for anatomic visualization, the Heartflow FFRCT Analysis for calculating fractional flow reserve, and the Heartflow Plaque Analysis for characterizing plaque burden. Heartflow serves imaging centers, hospitals, and physicians in the United States and internationally, including through adoption by NHS England. The company’s cloud-based technology integrates into existing clinical workflows to enhance diagnostic accuracy and efficiency.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Health Information Services Homepage heartflow.com
Sector Healthcare IR page ir.heartflow.com
Tags
cardiac imaging, artificial intelligence, coronary artery disease, computational fluid dynamics, medical software, diagnostic imaging, fractional flow reserve, plaque analysis, Heartflow Platform, Heartflow RoadMap Analysis, Heartflow FFRCT Analysis, Heartflow Plaque Analysis
Press page —

Metrics

Valuation  
Market cap $ 4.893B
Market cap (USD) $ 4.893B
P/E -17.58
PEG —
P/BV 17.32
P/S 27.80
P/OCF -90.58
P/FCF -82.87
Dividend yield —
Turnover / mcap —
Returns  
ROE -38.8%
ROI -42.9%
ROIC -17.7%
Profit margin -66.3%
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding Yes
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 37
Quality score -43.8%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023
Revenue 176.034M 125.808M 87.174M
Net profit -116.791M -96.426M -95.655M
Free cash flow -59.048M -73.358M -82.539M

Figure FY 2025 FY 2024 FY 2023
Share price 29.15 — —
P/FCF -42.1 — —

Filed figures

Figure Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) — — 24.6M 29.3M
↳ YoY growth +19.1%
Lease liabilities (USD) — — 24M 22.1M
Cash and deposits (USD) 41M 127M 51.4M 44.8M
Right-of-use assets (USD) — — 18.8M 17.5M
Cash flow detail
Operating cash flow (USD) — -76.4M -69M -54M
Purchases of property, plant and equipment (USD) — -6.11M -4.36M -5.03M
Change in receivables (cash effect) (USD) — -9.35M -3.85M -4.89M
Change in payables (cash effect) (USD) — -623,000 -327,000 218,000
Share buybacks (cash effect) (USD) — -228,000 — —
Interest paid (cash effect) (USD) — -20.8M -19.2M -8.57M
Income taxes paid (cash effect) (USD) — -405,000 — 0.00
Share-based compensation (USD) — 11.9M 10.2M 14M
Operating cash flow before change in receivables (USD) — -67.1M -65.2M -49.1M
Free cash flow (OCF - PPE - intangibles) (USD) — -82.5M -73.4M -59M
Income detail
Research and development expense (USD) — 35.9M 43.5M 64.9M
Total comprehensive income (USD) — -96.2M -96.7M -116M
Comprehensive income to owners (USD) — -96.2M -96.7M -116M
Provision for credit losses (USD) — 1.19M -244,000 188,000
Credit cost ratio (credit losses / average receivables) (%) — — — 0.7%
Reported Mar 18, 2026 Mar 18, 2026 Mar 18, 2026 Mar 18, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

SAN FRANCISCO — November 12, 2026 – Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for diagnosing and managing coronary artery disease (CAD), today reported financial results for the third quarter ended September 30, 2026.

Third Quarter 2026 Highlights

Ï

Total revenue of $72.9 million, a 57% increase year-over-year

Ï

Gross margin of 83.6%, non-GAAP gross margin of 83.8%

Ï

Net operating loss of $13.8 million; non-GAAP net operating loss of $5.0 million

2026 Annual Guidance

Ï

Total revenue of $262 million to $264 million (approximately 49% to 50% growth year-over-year), compared to previous guidance of $246 million to $250 million (approximately 40% to 42% growth year-over-year)

Ï

Non-GAAP gross margin of approximately 82.5%, compared to previous guidance of approximately 82%

“Our third quarter was excellent, with revenue accelerating for the third consecutive quarter and U.S. revenue growing at its fastest pace in 11 quarters,” said John Farquhar, President and CEO of Heartflow.

Press Alt+1 for screen-reader mode, Alt+0 to cancelAccessibility Screen-Reader Guide, Feedback, and Issue Reporting | New window

Skip to content

Release Details

Heartflow to Report Third Quarter 2026 Financial Results on November 12, 2026

October 19, 2026

PDF Version

SAN FRANCISCO, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for diagnosing and managing coronary artery disease (CAD), today announced it will release financial results for the third quarter of 2026 after market close on Thursday, November 12, 2026. Management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET on November 12, 2026.

Those interested in listening to the conference call should register online using this link. Once registered, participants will receive dial-in numbers and a unique PIN to join the call. Participants are encouraged to register more than 15 minutes prior to the start of the call. A live and archived webcast of the event will also be available on the “Investor Relations” section of the Heartflow website at https://ir.heartflow.com. The archived version will be available for 12 months following completion of the live call.

About Heartflow’s Technology and Research Heartflow’s technology is redefining precision diagnostic testing and management for coronary artery disease (CAD) through clinically-proven AI and the world’s largest coronary imaging dataset. Heartflow has been adopted by more than 1,800 institutions globally and continues to strengthen its commercial presence to make this cutting-edge solution more widely available to an increasingly diverse patient population. Backed by American College of Cardiology and American Heart Association (ACC/AHA) guidelines and supported by more than 625 peer-reviewed publications, Heartflow has redefined how clinicians manage care for over 750,000 patients worldwide.1 Key benefits include:

  • Unmatched proprietary data pipeline: Built from the world’s largest database of more than 250 million annotated CTA images, Heartflow’s data foundation powers advanced AI models that deliver highly accurate, reproducible diagnostic insights across diverse patient populations.

  • Extensive clinical and real-world validation: Heartflow’s AI-driven solutions have been validated through clinical evidence in over 200 studies assessing over 365,000 patients. Heartflow is the only AI platform prospectively validated against invasive gold standards and demonstrated through real-world evidence to improve patient outcomes.2,3,4,5 Proven in real-world practice with reproducibility and accuracy, Heartflow’s coronary CTA image acceptance rates exceed 97%.

  • Seamless clinical integration via upgraded workflow: Heartflow delivers final quality-reviewed analyses instantly upon order, enabling clinicians to move from diagnosis to decision without delay.

  • **Quality system, global security and patient-data integrity compliance:**Heartflow meets or exceeds leading international standards, including HITRUST, SOC 2 Type 2, MDSAP, ISO 13485, and ISO 27001.

About Heartflow, Inc. Heartflow is transforming coronary artery disease from the world’s leading cause of death into a condition that can be detected early, diagnosed accurately, and managed for life. The Heartflow One platform uses AI to turn coronary CTA images into personalized 3D models of the heart, providing clinically meaningful, actionable insights into plaque location, volume, and composition and its effect on blood flow — all without invasive procedures. Discover how we’re shaping the future of cardiovascular care at heartflow.com.

Investor Contact Nick Laudico [email protected]

Media Contact Elliot Levy [email protected]


1 Gulati M, et al. 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCAI Guideline for the Evaluation and Diagnosis of Chest Pain. Circulation 2021; 144:e368–e454. 2 Narula, et al. EHJ CVI 2024. 3 Danad, et al. JAMA Cardiol 2017. 4 Fairbairn et al. Coronary CT Angiography Plaque as a Predictor of Death, Cardiovascular Death and Myocardial Infarction. Presented at AHA 2025. (Real-world study with n=7,899 patients, higher TPV results in increased cardiovascular death and MI). 5 Madsen KT, et al. ADVANCE-DK 7-year. Presented at TCT Scientific Sessions 2024. (n=900 patients determined a 2.5x increase in cardiovascular events or deaths at 7 years).

Investor Contact

Nick Laudico Vice President, Investor Relations [email protected]

Subscribe to our email alerts

Press Alt+1 for screen-reader mode, Alt+0 to cancelAccessibility Screen-Reader Guide, Feedback, and Issue Reporting | New window

Skip to content

Release Details

Heartflow to Participate in the Wells Fargo 21st Annual Healthcare Conference

August 27, 2026

PDF Version

SAN FRANCISCO, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for diagnosing and managing coronary artery disease (CAD), today announced that members of management will participate in a fireside chat at the upcoming Wells Fargo 21st Annual Healthcare Conference. The fireside chat, which will include a slideshow presentation followed by a question-and-answer session, will take place in Boston on Wednesday, September 9, 2026, at 3:45 p.m. ET / 12:45 p.m. PT.

A live and archived version of the fireside chat will be available on the Investor Relations section of the Heartflow website at https://ir.heartflow.com.

About Heartflow’s Technology and Research

Heartflow’s technology is redefining precision diagnostic testing and management for coronary artery disease (CAD) through clinically-proven AI and the world’s largest coronary imaging dataset. Heartflow has been adopted by more than 1,800 institutions globally and continues to strengthen its commercial presence to make this cutting-edge solution more widely available to an increasingly diverse patient population. Backed by American College of Cardiology and American Heart Association (ACC/AHA) guidelines and supported by more than 625 peer-reviewed publications, Heartflow has redefined how clinicians manage care for over 750,000 patients worldwide.1 Key benefits include:

  • Unmatched proprietary data pipeline: Built from the world’s largest database of more than 200 million annotated CTA images, Heartflow’s data foundation powers advanced AI models that deliver highly accurate, reproducible diagnostic insights across diverse patient populations.

  • Extensive clinical and real-world validation: Heartflow’s AI-driven solutions have been validated through clinical evidence in over 200 studies assessing over 365,000 patients. Heartflow is the only AI platform prospectively validated against invasive gold standards and demonstrated through real-world evidence to improve patient outcomes.2,3,4,5 Proven in real-world practice with reproducibility and accuracy, Heartflow’s coronary CTA image acceptance rates exceed 97%.

  • Seamless clinical integration via upgraded workflow: Heartflow delivers final quality-reviewed analyses instantly upon order, enabling clinicians to move from diagnosis to decision without delay.

  • Quality system, global security and patient-data integrity compliance: Heartflow meets or exceeds leading international standards, including HITRUST, SOC 2 Type 2, MDSAP, ISO 13485, and ISO 27001.

About Heartflow, Inc.

Heartflow is transforming coronary artery disease from the world’s leading cause of death into a condition that can be detected early, diagnosed accurately, and managed for life. The Heartflow One platform uses AI to turn coronary CTA images into personalized 3D models of the heart, providing clinically meaningful, actionable insights into plaque location, volume, and composition and its effect on blood flow — all without invasive procedures. Discover how we’re shaping the future of cardiovascular care at heartflow.com.

Investor Contact Nick Laudico [email protected]

Media Contact Elliot Levy [email protected]


1 Gulati M, et al. 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCAI Guideline for the Evaluation and Diagnosis of Chest Pain. Circulation 2021; 144:e368–e454. 2 Narula, et al. EHJ CVI 2024. 3 Danad, et al. JAMA Cardiol 2017. 4 Fairbairn et al. Coronary CT Angiography Plaque as a Predictor of Death, Cardiovascular Death and Myocardial Infarction. Presented at AHA 2025. (Real-world study with n=7,899 patients, higher TPV results in increased cardiovascular death and MI). 5 Madsen KT, et al. ADVANCE-DK 7-year. Presented at TCT Scientific Sessions 2024. (n=900 patients determined a 2.5x increase in cardiovascular events or deaths at 7 years).

Investor Contact

Nick Laudico Vice President, Investor Relations [email protected]

Subscribe to our email alerts

Prompts

Heartflow, Inc. (ticker HTFL), listed in United States.

Company History

Date Change Detail
Sep 1, 2010 Renamed Cardiovascular Simulation, Inc. → HEARTFLOW, INC.

ETFs Holding Heartflow, Inc.

ETF Weight in ETF Shares Market value As of
FMED 2.59% 26,500 $ 1.335M Aug 31, 2026
BCSM 1.25% 14,146 $ 415.044K Jun 30, 2026
MMSC 0.31% 3,311 $ 155.153K Nov 16, 2026
FSEG 0.26% 502 $ 14.729K Jun 30, 2026
IQM 0.06% 2,554 $ 74.934K Jun 30, 2026
FBCG 0.04% 106,405 $ 2.685M Jul 31, 2026
FESM 0.01% 26,213 $ 769.089K Jun 30, 2026